Related Experiment Video
Updated: Mar 27, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia
Hsin-Yun Lin1,2,3,4, Sokchea Khou2,4, Evan Lind4,5
1Division of Oncological Sciences, Oregon Health & Science University, Portland, OR, United States.
Introduction:
Tousled-like kinase 2 (TLK2) is a serine/threonine kinase that plays a role in DNA replication, chromatin remodeling, and DNA damage response. TLK2 has been implicated in the pathogenesis of various types of cancer, including breast cancer, glioblastoma, and acute myeloid leukemia (AML). However, no potent and selective TLK2 inhibitors have been developed.
Methods:
We evaluated the efficacy of a human TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML cell lines. To assess in vivo efficacy and toxicity, we administered a mouse TLK2 ASO alone or in combination with gilteritinib in a murine model of AML.
Results:
TLK2 ASO treatment resulted in a dose-dependent reduction of TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity observed when combined with gilteritinib. In a murine AML model, TLK2 ASO achieved approximately 50% knockdown efficiency. Both TLK2 ASO alone and in combination with gilteritinib significantly reduced spleen size, leukemia burden, and bone marrow progenitor cell populations. The treatment was generally well tolerated, with only minimal toxicity observed.
Discussion:
This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Future efforts should focus on improving ASO delivery and knockdown efficiency to maximize therapeutic benefit.
Insights
This study shows that a Tousled-like kinase 2 (TLK2) antisense oligonucleotide (ASO) effectively reduces acute myeloid leukemia (AML) cells, especially when combined with gilteritinib. The TLK2 ASO treatment demonstrated promising efficacy and tolerability in preclinical AML models.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tousled-like kinase 2 (TLK2) is a serine/threonine kinase involved in DNA replication, chromatin remodeling, and DNA damage response.
- TLK2 is implicated in the pathogenesis of various cancers, including acute myeloid leukemia (AML), but potent and selective inhibitors are lacking.
Purpose of the Study:
- To evaluate the efficacy of a TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML.
- To assess the in vivo efficacy and toxicity of TLK2 ASO in a murine model of AML.
Main Methods:
- Evaluated TLK2 ASO and gilteritinib combination in AML cell lines.
- Administered mouse TLK2 ASO alone or with gilteritinib in a murine AML model to assess in vivo efficacy and toxicity.
Main Results:
- TLK2 ASO reduced TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity when combined with gilteritinib.
- In vivo, TLK2 ASO achieved ~50% knockdown efficiency and significantly reduced spleen size, leukemia burden, and bone marrow progenitor cells.
- The combination treatment was well tolerated with minimal toxicity.
Conclusions:
- TLK2 ASO represents a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition.
- This approach may also be applicable to other TLK2-driven cancers.
- Future research should focus on optimizing ASO delivery and knockdown efficiency for maximal therapeutic benefit.
